Complementary Feeding: A Position Paper by the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Committee on Nutrition

Fewtrell, Mary; Bronsky, Jiri; Campoy, Cristina; Domellöf, Magnus; Embleton, Nicholas; Fidler Mis, Nataša; Hojsak, Iva; Hulst, Jessie M.; Indrio, Flavia; Lapillonne, Alexandre; Molgaard, Christian

Journal of Pediatric Gastroenterology and NutritionJanuary 2017Vol. 64 - Issue 1: p 119–132

Abstract

This position paper on complementary feeding summarizes evidence for health effects of complementary foods. It focuses on healthy infants in Europe. After reviewing current knowledge and practices, we have formulated these conclusions: Exclusive or full breast-feeding for about 6 months is a desirable goal. Complementary feeding (ie, solid foods and liquids other than breast milk or infant formula and follow-on formula) should not be introduced before 17 weeks and not later than 26 weeks.

ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

J. Bousquet, P. W. Hellings, I. Agache, A. Bedbrook, C. Bachert, K. C. Bergmann, M. Bewick, C. Bindslev-Jensen, S. Bosnic-Anticevitch, C. Bucca, D. P. Caimmi, P. A. M. Camargos, G. W. Canonica, T. Casale, N. H. Chavannes et al.

Open Access Review

Abstract

The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA—disseminated and implemented in over 70 countries globally—is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves.

Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies

• Clin Transl Allergy
• v.6; 2016
• PMC5120439

Clin Transl Allergy. 2016; 6: 41.

An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project

M. A. Calderon,1 P. Demoly,2 T. Casale,3 C. A. Akdis,4 C. Bachert,5 M. Bewick,6 B. M. Bilò,7 B. Bohle,8 S. Bonini,9 A. Bush,1 D. P. Caimmi,2 G. W. Canonica,10 V. Cardona,11 A. M. Chiriac,12 L. Cox,13 A. Custovic,1 F. De Blay,14 P. Devillier,15 A. Didier,16 G. Di Lorenzo,17 G. Du Toit,18 S. R. Durham,19 P. Eng,20 A. Fiocchi,21 A. T. Fox,22 R. Gerth van Wijk,23 R. M. Gomez,24 T. Haathela,25 S. Halken,26 P. W. Hellings,27 L. Jacobsen,28 J. Just,29 L. K. Tanno,30,31,32 J. Kleine-Tebbe,33 L. Klimek,34 E. F. Knol,35 P. Kuna,36 D. E. Larenas-Linnemann,37,38 A. Linneberg,39,40,41 M. Matricardi,42 H. J. Malling,43 R. Moesges,44 J. Mullol,45 A. Muraro,46 N. Papadopoulos,47 G. Passalacqua,48 E. Pastorello,49 O. Pfaar,50,51,52 D. Price,53,54,55 P. Rodriguez del Rio,56 R. Ruëff,57 B. Samolinski,58 G. K. Scadding,59,60 G. Senti,61 M. H. Shamji,62,63 A. Sheikh,64 J. C. Sisul,65 D. Sole,66 G. J. Sturm,67,68 A. Tabar,69 R. Van Ree,70 M. T. Ventura,71 C. Vidal,72 E. M. Varga,73 M. Worm,74 T. Zuberbier,74 and J. Bousquet31,75,76,77,78

Author information ► Article notes ► Copyright and License information ►

Abstract

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults.

The Social Value of Childhood Vaccination in the United States

Vaccination of children born in the United States in 2009 will save 1.2 million quality-adjusted life-years, generating $184 billion in social value net of vaccination costs.

Tomas J. Philipson, PhD; Julia Thornton Snider, PhD; Ayman Chit, PhD; Sarah Green, BA; Philip Hosbach, BA; Taylor Tinkham Schwartz, MPH; Yanyu Wu, PhD; and Wade M. Aubry, MD

ABSTRACT

Objectives: To determine the lifetime social value of using the guideline-recommended vaccines for children born in the United States in 2009. 

Study Design: This study utilized an economic model with parameter values sourced from clinical and observational data, as well as the literature. 

Immunopathogenesis of granulomas in chronic autoinflammatory diseases

Review

Citation: Clinical & Translational Immunology (2016) 5, e118; doi:10.1038/cti.2016.75
Published online 16 December 2016

OPEN

Wilhelmina Maria Cornelia Timmermans^1,2,3, Jan Alexander Michael van Laar^1,2, Petrus Martinus van Hagen^1,2 and Menno Cornelis van Zelm³

1. ¹Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
2. ²Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
3. ³Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia

of page

Abstract

Granulomas are clusters of immune cells. These structures can be formed in reaction to infection and display signs of necrosis, such as in tuberculosis. Alternatively, in several immune disorders, such as sarcoidosis, Crohn’s disease and common variable immunodeficiency, non-caseating granulomas are formed without an obvious infectious trigger. Despite advances in our understanding of the human immune system, the pathogenesis underlying these non-caseating granulomas in chronic inflammatory diseases is still poorly understood. Here, we review the current knowledge about the immunopathogenesis of granulomas, and we discuss how the involved immune cells can be targeted with novel therapeutics.

• Table of contents
• Download PDF
• Send to a friend
• View interactive PDF in ReadCube
• Rights and permissions
• Order Commercial Reprints
• Abstract
• Introduction
• Chronic autoinflammatory diseases with granuloma formation
• Key players in granuloma pathogenesis
• Therapeutic implications
• Conclusions
• Conflict of interest
• References
• Acknowledgements
• Figures and Tables

• Export citation
• Export references

Cross-reactive LTP sensitization in food-dependent exercise-induced urticaria/anaphylaxis: a pilot study of a component-resolved and in vitro depletion approach

Clinical and Translational Allergy

BRIEF COMMUNICATION

 

OPEN ACCESS

• Diana Margarida Gonçalves Solha Pereira da SilvaEmail authorView ORCID ID profile,
• Teresa Maria Silva Vieira,
• Ana Maria Alves Pereira,
• André Miguel Afonso de Sousa Moreira and
• José Luís Dias Delgado

Clinical and Translational Allergy20166:46

DOI: 10.1186/s13601-016-0136-5

©  The Author(s) 2016

Received: 18 June 2016

Accepted: 29 November 2016

Published: 22 December 2016

Abstract

Background

Challenge tests for food-dependent exercise-induced anaphylaxis (FDEIA) carry some risk and have a high rate of false negatives. Our aim was to explore the usefulness of an in vitro immunodepletion assay and an allergen microarray test in the identification of IgE-mediated cross-reactive food allergens in patients with suspected FDEIA or food-dependent exercise-induced urticaria and panallergen sensitization.

Pesticides Are Associated with Allergic and Non-Allergic Wheeze among Male Farmers

Environ Health Perspect; DOI:10.1289/EHP315

Jane A. Hoppin,1 David M. Umbach,2 Stuart Long,3 Stephanie J. London,4 Paul K. Henneberger,5 Aaron Blair,6 Michael Alavanja,6 Laura E. Beane Freeman,6 and Dale P. Sandler4

Author Affiliations open

 PDF Version (392 KB)

• Abstract
• About This Article
• Supplemental Material

• 
  
• Background: Growing evidence suggests that pesticide use may contribute to respiratory symptoms.
  Objective: To evaluate the association of currently used pesticides with allergic and non-allergic wheeze among male farmers.

Vitamin D Status and Efficacy of Vitamin D Supplementation in Atopic Dermatitis: A Systematic Review and Meta-Analysis

Open AccessArticle

Nutrients 2016, 8(12), 789; doi:10.3390/nu8120789
Min Jung Kim ¹

,Soo-Nyung Kim ²

,Yang Won Lee ^1,3,* ,Yong Beom Choe ^1,3

 andKyu Joong Ahn ^1,3

¹Department of Dermatology, Konkuk University School of Medicine, Seoul 05030, Korea²Department of Obstetrics and Gynecology, Konkuk University School of Medicine, Seoul 05030, Korea³Research Institute of Medical Science, Konkuk University, Seoul 05030, Korea

Abstract
Recent literature has highlighted the possible role of vitamin D in atopic dermatitis (AD), and that vitamin D supplementation might help to treat AD. This study determined the relationship between vitamin D level and AD, and assessed the efficacy of vitamin D supplementation. We searched the MEDLINE, EMBASE, and Cochrane databases up to May 2015. Observational studies and randomized controlled trials were included based on the available data on the serum 25-hydroxyvitamin D (25(OH)D) level and quantified data available for severity assessed using the Scoring Atopic Dermatitis (SCORAD) index or Eczema Area and Severity Index (EASI) score.